| Title: | Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins |
| Journal: | Circulation Genomic and Precision Medicine |
| Published: | 10 Feb 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/41664920/ |
| DOI: | https://doi.org/10.1161/circgen.125.005345 |
Publication 18321
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition is a potent cholesterol-lowering strategy. This study examined the effects of PCSK9 monoclonal antibodies (mAbs) and high-intensity statins beyond low-density lipoprotein cholesterol reduction, which are not fully defined, particularly in patients with acute myocardial infarction (MI).</p>
METHODS: Proteomic and lipidomic analyses were conducted on plasma from 265 patients with acute MI from the PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) randomized, placebo-controlled PCSK9 mAb trial and 34 patients without MI with hyperlipidemia from the Vienna Lipid Clinic registry, also receiving PCSK9 mAbs.</p>
RESULTS: Discovery proteomics revealed changes in apolipoproteins and increased PCOLCE (procollagen C-endopeptidase enhancer 1) levels in both the PCSK9 mAb and placebo groups after MI. UK Biobank data confirmed PCOLCE and PCSK9 upregulation as associated with statin use. Hepatoma cell experiments demonstrated a dose-dependent PCOLCE induction on statin treatment. Compared with placebo (statins only), PCSK9 mAb therapy resulted in greater reductions in APOB (apolipoprotein B), APOE (apolipoprotein E), APOC2 (apolipoprotein C2), and APOC3 (apolipoprotein C3), as shown by targeted proteomics. Mediation analysis indicated that these changes were largely explained by low-density lipoprotein cholesterol lowering. Lipidomics identified more pronounced reductions in cholesteryl esters, ceramides, sphingomyelins, phosphatidylcholines, triglycerides, and diglycerides in PCSK9 mAb-treated patients with MI. Results were largely consistent in patients without MI. However, levels of LPA (apolipoprotein[a]), the characteristic protein component of lipoprotein(a), remained unchanged in PCSK9 mAb-treated patients with MI, since a rise of LPA was observed in the placebo group post-MI.</p>
CONCLUSIONS: Most apolipoprotein changes after PCSK9 mAb therapy following MI were mediated by low-density lipoprotein cholesterol lowering. Statin use is associated with increased circulating PCOLCE, with hepatoma cell experiments supporting a predominant hepatic origin. Combining PCSK9 mAbs with high-intensity statins mitigates post-MI increases in lipoprotein(a).</p>
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03067844.</p>
14 Keywords
- Aged
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Cholesterol, LDL
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Lipidomics
- Male
- Middle Aged
- Myocardial Infarction
- PCSK9 Inhibitors
- Proprotein Convertase 9
- Proteomics
16 Authors
- Lukas E. Schmidt
- Sean A. Burnap
- Bhawana Singh
- Kaloyan Takov
- Sylvain Losdat
- Lore Schrutka
- Lukas Galli
- Konstantinos Theofilatos
- Georg W. Otto
- Christian Hengstenberg
- Ioanna Tzoulaki
- Irene M. Lang
- Konstantinos C. Koskinas
- Walter S. Speidl
- Lorenz Räber
- Manuel Mayr
1 Application
| Application ID | Title |
|---|---|
| 22102 | Multivariate approaches for the identification of novel environmental and genetic risk factors for neuropsychiatric disorders, skin cancers and bone-related outcomes. |
Enabling scientific discoveries that improve human health